MGTX
Neutral signalScored 2026-10-22 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
MeiraGTx Holdings plc
- Nom
- MeiraGTx Holdings plc
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $880.7M
- Employés
- 393
- PDG
- Alexandria Forbes
- Site web
- https://www.meiragtx.com
- Marché
- FDMTKRYSLCTXNTLAOCGNPASG
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 62 000 titres (~859 320,00 $ US)
- Insiders
- Forbes Alexandria
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,710,812
Avg sell (VWAP, 90d window) $11.75 vs last close $9.18 (-21.8%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,153,612 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-18
- Liquidity
- Thin $8,188,485/day · 20d vol
- Last synced
-
2026-10-26 21:10:40
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-20 | Giroux Richard | Sell · S | 56,000 | $9.95 | $557,200 | Form 4 |
| 2026-10-06 | Naylor Stuart | Sell · S · 10b5-1 | 27,659 | $10.64 | $294,292 | Form 4 |
| 2026-08-18 | Forbes Alexandria | Sell · S · 10b5-1 | 62,000 | $13.86 | $859,320 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-22 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
MGTX presents a meaningful event-driven catalyst — FDA Breakthrough Therapy Designation and a Q2 2026 earnings beat — that partially offsets deeply stressed fundamentals, including a current ratio below 1.0, negative…
The first sentence of the analysis written for MGTX on 2026-10-22 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $859K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $859K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Pulls against a bullish reading. Current ratio 0.75 · operating margin -130%
Suggested stop 8.49, nearest stored support minus 0.5 ATR(7.6% under the last close). Reward/risk to the next stored resistance is 0.05. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-09-30 Financial Contrast: MeiraGTx (NASDAQ:MGTX) & aTyr Pharma (NASDAQ:ATYR) MeiraGTx (NASDAQ: MGTX - Get Free Report) and aTyr Pharma (NASDAQ: ATYR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Valuation and Earnings This table compares MeiraGTx and
- 2026-09-23 MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors.
- 2026-09-11 Head-To-Head Analysis: Ascendis Pharma A/S (NASDAQ:ASND) versus MeiraGTx (NASDAQ:MGTX) Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) and MeiraGTx (NASDAQ: MGTX - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability. Profitability This table compares Ascendis Pharma A/S and
- 2026-08-26 Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in S
- 2026-08-26 Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical GV101, a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patients who had failed at least two prior lines of therapy. GV101''s 24-week bORR exceeds published 6-month bORRs for all existing, approved steroid-refractory cGvHD therapies.
- 2026-08-13 MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates MeiraGTx Holdings PLC (MGTX) came out with quarterly earnings of $1.71 per share, beating the Zacks Consensus Estimate of a loss of $0.39 per share. This compares to a loss of $0.48 per share a year ago.
- 2026-08-13 MeiraGTx Reports Second Quarter 2026 Financial and Operational Results Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition Secured up to $400 million strategic investment from Oberland Capital, with up to $375 million in non-dilutive capital to support development and commercialization of AAV2-hAQP1 and bota-vec Anticipate submission of global regulatory filings for approval of bota-vec in 2026 and potential BLA filing for AAV2-hAQP1 in mid-2027 LONDON and NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the second quarter ended June 30, 2026, and provided a corporate update. “During the second quarter of 2026, we made tremendous progress towards transforming MeiraGTx into a commercial company,” said Alexandria Forbes, Ph.D.
- 2026-08-11 Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich''s Ataxia Graviton received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a novel capsule formulation of GV101 on August 7, 2026. FDA clearance marks a critical regulatory milestone in advancing this formulation of GV101, a capsule with improved PK and oral availability, into human trials for Friedreich''s ataxia (FA).
- 2026-08-06 MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) LONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company''s Board of Directors approved equity awards under the Company''s 2026 Employment Inducement Award Plan to a new employee. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-07-30 Some Potential Merit Within MeiraGTx Holdings MeiraGTx Holdings plc is positioned potentially for significant upside with late-stage gene therapy assets targeting large, high-unmet-need indications. AAV2-hAQP1 for radiation-induced xerostomia could address a $3.7B peak sales market with no direct competition; pivotal Phase 2 data expected 2Q27. Robust optionality from GAD for Parkinson''s, bota-vec for XLRP, milestone payments, and the innovative Riboswitch platform enhances MGTX''s valuation case.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 94.0% | 28.5% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -125.3% | -404.2% | -505.0% | -783.1% | -210.3% | |
| Ebitda Margin | -109.9% | -365.7% | -407.1% | -729.1% | -189.4% | |
| Operating Profit Margin | -130.2% | -493.4% | -977.8% | -730.9% | -193.0% | |
| Pretax Profit Margin | -140.3% | -444.1% | -599.5% | -814.2% | -211.0% | |
| Continuous Operations Profit Margin | -140.3% | -444.1% | -599.5% | -814.2% | -211.0% | |
| Net Profit Margin | -140.3% | -444.1% | -599.5% | -814.2% | -211.0% | |
| Bottom Line Profit Margin | -140.3% | -444.1% | -599.5% | -814.2% | -211.0% | |
| Current Ratio | 0.749 | 2.032 | 2.380 | 1.881 | 2.690 | |
| Quick Ratio | 0.749 | 2.026 | 2.380 | 1.881 | 2.690 | |
| Solvency Ratio | -0.406 | -0.668 | -0.373 | -0.604 | -0.532 | |
| Cash Ratio | 0.538 | 1.705 | 1.932 | 1.407 | 2.021 | |
| Price To Earnings Ratio | -5.599 | -2.873 | -4.711 | -2.272 | -13.189 | |
| Price To Earnings Growth Ratio | 0.170 | -0.068 | 0.098 | -0.038 | -0.510 | |
| Forward Price To Earnings Growth Ratio | 0.170 | -0.068 | 0.098 | -0.038 | -0.510 | |
| Price To Earnings Diluted Ratio | -5.599 | -2.873 | -4.711 | -2.272 | -13.189 | |
| Price To Earnings Diluted Growth Ratio | 0.170 | -0.068 | 0.098 | -0.038 | -0.510 | |
| Price To Book Ratio | -110.378 | 6.269 | 2.870 | 2.502 | 5.652 | |
| Price To Sales Ratio | 7.856 | 12.777 | 28.290 | 18.502 | 27.794 | |
| Price To Free Cash Flow Ratio | -12.741 | -3.885 | -3.159 | -2.495 | -15.938 | |
| Price To Operating Cash Flow Ratio | -13.793 | -4.069 | -3.763 | -4.030 | -99.513 | |
| Debt To Assets Ratio | 0.363 | 0.314 | 0.273 | 0.290 | 0.074 | |
| Debt To Equity Ratio | -15.309 | 1.250 | 0.646 | 0.784 | 0.128 | |
| Debt To Capital Ratio | 1.070 | 0.556 | 0.392 | 0.439 | 0.113 | |
| Long Term Debt To Capital Ratio | 1.132 | 0.519 | 0.343 | 0.376 | 0.000 | |
| Financial Leverage Ratio | -42.194 | 3.977 | 2.365 | 2.703 | 1.727 | |
| Working Capital Turnover Ratio | 5.096 | 0.429 | 0.170 | 0.170 | 0.226 | |
| Operating Cash Flow Ratio | -0.378 | -1.719 | -1.571 | -0.891 | -0.155 | |
| Operating Cash Flow Sales Ratio | -0.570 | -3.140 | -7.517 | -4.592 | -0.279 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.083 | 1.047 | 1.191 | 1.615 | 6.244 | |
| Debt Service Coverage Ratio | -2.428 | -9.169 | -4.308 | -23.467 | -247.917 | |
| Interest Coverage Ratio | -8.688 | -12.373 | -10.348 | -23.525 | -252.632 | |
| Short Term Operating Cash Flow Coverage Ratio | -1.881 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.523 | -1.232 | -1.180 | -0.792 | -0.444 | |
| Capital Expenditure Coverage Ratio | -12.117 | -21.089 | -5.223 | -1.626 | -0.191 | |
| Dividend Paid And Capex Coverage Ratio | -12.117 | -21.089 | -5.223 | -1.626 | -0.191 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -7.402 | -3.339 | -6.243 | -2.337 | -13.080 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 94.0% | ▲65.5% | ▲9.5% |
| Ebit Margin | -125.3% | ▲278.9% | ▲280.2% |
| Ebitda Margin | -109.9% | ▲255.8% | ▲250.3% |
| Operating Profit Margin | -130.2% | ▲363.2% | ▲374.9% |
| Pretax Profit Margin | -140.3% | ▲303.8% | ▲301.5% |
| Continuous Operations Profit Margin | -140.3% | ▲303.8% | ▲301.5% |
| Net Profit Margin | -140.3% | ▲303.8% | ▲301.5% |
| Bottom Line Profit Margin | -140.3% | ▲303.8% | ▲301.5% |
| Current Ratio | 0.749 | ▼-1.283 | ▼-1.197 |
| Quick Ratio | 0.749 | ▼-1.277 | ▼-1.196 |
| Solvency Ratio | -0.406 | ▲0.262 | ▲0.110 |
| Cash Ratio | 0.538 | ▼-1.167 | ▼-0.983 |
| Price To Earnings Ratio | -5.599 | ▼-2.726 | ▲0.130 |
| Price To Earnings Growth Ratio | 0.170 | ▲0.237 | ▲0.239 |
| Forward Price To Earnings Growth Ratio | 0.170 | ▲0.237 | ▲0.239 |
| Price To Earnings Diluted Ratio | -5.599 | ▼-2.726 | ▲0.130 |
| Price To Earnings Diluted Growth Ratio | 0.170 | ▲0.237 | ▲0.239 |
| Price To Book Ratio | -110.378 | ▼-116.647 | ▼-91.761 |
| Price To Sales Ratio | 7.856 | ▼-4.921 | ▼-11.188 |
| Price To Free Cash Flow Ratio | -12.741 | ▼-8.856 | ▼-5.098 |
| Price To Operating Cash Flow Ratio | -13.793 | ▼-9.723 | ▲11.241 |
| Debt To Assets Ratio | 0.363 | ▲0.049 | ▲0.100 |
| Debt To Equity Ratio | -15.309 | ▼-16.559 | ▼-12.809 |
| Debt To Capital Ratio | 1.070 | ▲0.514 | ▲0.556 |
| Long Term Debt To Capital Ratio | 1.132 | ▲0.613 | ▲0.658 |
| Financial Leverage Ratio | -42.194 | ▼-46.171 | ▼-35.910 |
| Working Capital Turnover Ratio | 5.096 | ▲4.668 | ▲3.878 |
| Operating Cash Flow Ratio | -0.378 | ▲1.341 | ▲0.564 |
| Operating Cash Flow Sales Ratio | -0.570 | ▲2.570 | ▲2.650 |
| Free Cash Flow Operating Cash Flow Ratio | 1.083 | ▲0.035 | ▼-1.153 |
| Debt Service Coverage Ratio | -2.428 | ▲6.741 | ▲55.030 |
| Interest Coverage Ratio | -8.688 | ▲3.685 | ▲52.825 |
| Short Term Operating Cash Flow Coverage Ratio | -1.881 | ▼-1.881 | ▼-1.505 |
| Operating Cash Flow Coverage Ratio | -0.523 | ▲0.710 | ▲0.312 |
| Capital Expenditure Coverage Ratio | -12.117 | ▲8.972 | ▼-4.068 |
| Dividend Paid And Capex Coverage Ratio | -12.117 | ▲8.972 | ▼-4.068 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -7.402 | ▼-4.062 | ▼-0.921 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $639.4M | $425.2M | $396.5M | $294.6M | $1.05B | |
| Enterprise value | $662.2M | $406.4M | $356.2M | $271.3M | $933.9M | |
| EV / Sales | 8.14x | 12.21x | 25.41x | 17.04x | 24.77x | |
| EV / Op. cash flow | -14.28x | -3.89x | -3.38x | -3.71x | -88.69x | |
| EV / Free cash flow | -13.20x | -3.71x | -2.84x | -2.30x | -14.21x | |
| EV / EBITDA | -7.40x | -3.34x | -6.24x | -2.34x | -13.08x | |
| Net debt / EBITDA | -0.25x | 0.15x | 0.71x | 0.20x | 1.60x | |
| Current ratio | 0.75x | 2.03x | 2.38x | 1.88x | 2.69x | |
| Income quality | 0.41x | 0.71x | 1.25x | 0.56x | 0.13x | |
| Graham net-net | -$2 | -$1 | -$1 | -$1 | $1 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 112.0% | 109.9% | 118.7% | 104.0% | 100.4% | |
| Working capital | -$30.8M | $62.7M | $92.5M | $72.3M | $115.1M | |
| Invested capital | $111.7M | $199.2M | $249.9M | $228.4M | $244.0M | |
| Return on assets | -46.7% | -54.8% | -25.7% | -40.7% | -24.9% | |
| Operating ROA | -41.2% | -55.1% | -42.5% | -36.5% | -21.3% | |
| Return on tangible assets | -46.8% | -55.0% | -25.8% | -41.0% | -25.1% | |
| Return on equity | 1971.4% | -217.9% | -60.8% | -110.1% | -42.9% | |
| Return on invested capital | -70.9% | -77.1% | -51.9% | -48.5% | -28.5% | |
| Return on capital employed | -86.9% | -78.6% | -52.8% | -49.3% | -28.9% | |
| Earnings yield | -17.9% | -34.8% | -21.2% | -44.0% | -7.6% | |
| Free cash flow yield | -7.8% | -25.7% | -31.7% | -40.1% | -6.3% | |
| Capex / Op. cash flow | -8.3% | -4.7% | -19.1% | -61.5% | -524.4% | |
| Capex / Depreciation | 30.5% | 38.6% | 147.0% | 522.6% | 701.3% | |
| Capex / Sales | 4.7% | 14.9% | 143.9% | 282.4% | 146.5% | |
| SG&A / Sales | 65.0% | 162.9% | 337.4% | 292.4% | 116.1% | |
| R&D / Sales | 159.3% | 359.0% | 740.4% | 538.5% | 176.9% | |
| Stock comp / Sales | 27.2% | 75.7% | 197.7% | 179.8% | 55.1% | |
| Intangibles / Total assets | 0.2% | 0.3% | 0.3% | 0.7% | 0.8% | |
| Days sales outstanding | 82d | 117d | 610d | 665d | 339d | |
| Days payables outstanding | 759d | 362d | 0d | 0d | 0d | |
| Operating cycle | 82d | 122d | 610d | 665d | 339d | |
| Cash conversion cycle | -677d | -239d | 610d | 665d | 339d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years